Abstract��OBJECTIVE To explore the role of clinical pharmacist in the individualized treatment for lung transplantation patients, using a case of lung transplantation patient after paraquat poisoning. METHODS Clinical pharmacist was involved in the treatment of lung transplant recipient and provided the full range of clinical pharmacy services, by adjusting and optimizing the medication regimen according to the patient��s condition and the monitoring results of therapeutic drug, paying attention to drug interaction, drug efficacy, adverse reactions and providing education of patient medication. RESULTS The infection was effectively controlled and the blood concentration of tacrolimus was maintained within the effective treatment window which avoided the serious adverse reactions, by optimizing the treatment plan. The medication adherence was improved by providing medication education for patient. CONCLUSION It is beneficial to promote rational drug use and improve the safety and effectiveness of the drug treatment for clinical pharmacist to go into clinical practice, and carry out pharmaceutical care for lung transplant recipient.
����, ���, ���, �Ϻ���, ������. �ٴ�ҩʦ����1������ֲ���߸��廯���Ƶ�ҩѧʵ��[J]. �й�ҩѧ��־, 2019, 54(10): 834-838.
LI Na, LIU Nan, TANG Shu, MENG Hai-yang, ZHANG Xiao-jian. Pharmaceutical Practice of Individualized Treatment for a Patient after Lung Transplantation by Clinical Pharmacist. Chinese Pharmaceutical Journal, 2019, 54(10): 834-838.
STEHLIK J, EDWARDS L B, KUCHERYAVAYA A Y, et al. The registry of the international society for heart and lung transplantation:twenty-sixth official adult lung and heart-lung transplantation report-2009. J Heart Lung Transplant,2009,28(10):1031-1049.
[2]
WU B, CHEN J Y. Progress in prevention and treatment of infection after lung transplantation. Chin J Organ Transplant(�л�������ֲ��־),2015,36(5):298-301.
[3]
CAI X J, SONG H Z, JIAO Z,et al. Distribution and drug resistance characteristics of pathogens for infection after lung transplantation from 2010 to 2016. Chin J Organ Transplant(�л�������ֲ��־),2017,38(9):513-519.
[4]
HUAN G, DENG Z D, NI Y X, et al. Chinese experts�� consensus on prevention and control of multidrug resistance organism healthcare-associated infection. Chin J Infect Control(�й���Ⱦ������־),2015,14(1):1-9.
[5]
SOLE A, SALAVERT M. Fungal infections after lung transplantation. Curr Opin Pulm Med,2009,15(3):243-253.
[6]
NEOH C F, SNELL G I, KOTSIMBOS T, et al. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant,2011,11(2):361-366.
[7]
CHINESE MEDICAL ASSOCIATION BRANCH OF ORGAN TRANSPLANTATION,CHINESE MEDICAL DOCTOR ASSOCIATION BRANCH OF ORGAN TRANSPLANT PHYSICIAN. Guidelines for the diagnosis and treatment of invasive fungal disease for solid organ transplant recipients in China(2016). Chin J Organ Transplant(�л�������ֲ��־),2016,37(5):300-305.
[8]
MA X,ZHAO L,WANG X X,et al. Advances in research on pharmacokinetic characteristics and therapeutic drug monitoring for the antifungal extended-spectrum posaconazole. Chin Pharm J(�й�ҩѧ��־), 2016,51(6):433-436.
[9]
CONTE J E,DEVOE C,LITTLE E,et al. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother, 2010,54(9):3609-3613.
[10]
FISHMAN J A. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis,2001,33(8):1397-1405.
[11]
HUMAR A, SNYDMAN D. AST INFECTIONS DISEASES COMMUNITY OF PRACTICE. Cytomegalovirus in solid organ transplant recipients . Am J Transplant, 2009,9(suppl 4):78-86.
[12]
CHINESE MEDICAL ASSOCIATION BRANCH OF ORGAN TRANSPLANTATION, CHINESE MEDICAL DOCTOR ASSOCIATION BRANCH OF ORGAN TRANSPLANT PHYSICIAN. Guidelines for the diagnosis and treatment of cytomegalovirus infection for solid organ transplant recipients in China(2016). Chin J Organ Transplant(�л�������ֲ��־),2016,37(9):561-565.
[13]
SCHEFFERT J L,RAZA K. Immunosuppression in lung transplantation. J Thorac Dis,2014,6(8):1039-1053.
[14]
DING Q,FENG D H. CYP3A5 gene polymorphisms and clinical rational use of drug. Pharm J Chin PLA(��ž�ҩѧѧ��),2015,31(5):435-438.
[15]
CHEN Y M,LI Y,HAN Z Y,et al. Effect of CYP3A5 genetic polymorphisms on the blood concentration of tacrolimus. J Clin Rehabil Tissue Eng Res(�й���֯�����о����ٴ�����),2008,12(31):6055-6059.
[16]
CHEN C,ZHANG Y J,HE X L, et al. Interpretation of tacrolimus guidelines for individualized medication. J Med Postgra(ҽѧ�о���ѧ��),2017,30(4):342-347.
[17]
ZHANG R L, LI Z D, LIU M, et al. Influential factors of blood steady state trough concentration of FK506 in patients undergoing renal transplant. Eval Anal Drug-Use Hosp China(�й�ҽԺ��ҩ���������),2012,12(3):233-235.
[18]
TENG L C, WANG C X, CHEN L Z, et al. Effect of diarrhea on tacrolimus blood trough levels in kidney transplantation recipients. J Nephrol Dialy Transplant(���ಡ��������ֲ��־),2009,18(5):406-409.
[19]
SANSONE-PARSONS A, KRISHNA G, MARTINHO M, et al.Effect of oral posaconazoleon the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy, 2007, 27(6): 825-834.
2019, Vol. 54 
